This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Good day and welcome to the Goodrich Petroleum First Quarter 2018 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there'll be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded.
GDRRQ GDUEQ GDAOQ GDANQ GDPMQ GDP GDPM GDPAN GDPAQ
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
GDPMQ RACE PXD GDAOQ CATO GDRRQ AMC IAC PDCE SM IPXL BKE CCL ESTE BRK.A GDP CLDR GOOGL PNC FCAU BA GDPAN GDPAQ WFCNP LMT FB AIHS RCUS CPE GST-A EGY NOVN RAD BWB GST-B WFC.PRL SLP GST WFC.PRJ LB ETH AXAS ADBE GST.PRA GST.PRB WFC.PRT MYL WFC.PRR WFC.PRQ SELB WFC.PRP RYN WFC.PRO WFC.PRN AAPL CCL AMR WFC.PRY WFC.PRX DAL WFC.PRW BBBY DIS WFC.PRV WFC WFC.WS C GDPM CMCSA COST GDUEQ SIX PGEM BLK GDANQ JPM ZUMZ WRD BYD
Every now and then the elephant in the run stomps and makes a lot of noise. Investors had better pay attention because the problem that everyone hoped would never be voiced now makes the front pages followed by potentially more stock impact.
CRC PTQEP GDPMQ CHKVP SDRPQ CHKDH CHKVZ CHKDG CHKDJ GDAOQ CHKDP CHK.PRD GDRRQ CKRGZ GDPM HKRCP HK.WS SD CHKWZ GDUEQ SDOCQ GDANQ GDP CHK CHK.WI HK GDPAN SDRXP PQ SDRXQ GDPAQ
12h - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
13h - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET